ID
16702
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Relapse Report
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords
Versions (1)
- 8/1/16 8/1/16 -
Uploaded on
August 1, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Description
New Lesion Specification
Description
Lesion number
Data type
integer
Alias
- UMLS CUI [1,1]
- C0221198
- UMLS CUI [1,2]
- C0750480
Description
Provide relevant code number for Method of Evaluation and Disease Site. lf "Other'' applies, use code 99 and specify.
Data type
integer
Alias
- UMLS CUI [1]
- C2911685
Description
Method of Evalution
Data type
text
Alias
- UMLS CUI [1]
- C2911685
Description
Site of Lesion
Data type
integer
Alias
- UMLS CUI [1]
- C0449685
Description
Disease Site
Data type
text
Alias
- UMLS CUI [1]
- C0449685
Description
Date of Evaluation
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0221198
- UMLS CUI [1,3]
- C0031809
Similar models
Relapse Report, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0750480 (UMLS CUI [1,2])
C0221198 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,3])